Teicoplanin, a new glycopeptide antibiotic, is structurally related to ristocetin, an antibiotic known to induce human platelet agglutination and, thus, thrombocytopenia and thromboembolic side effects. The aim of this study was to evaluate the effects of teicoplanin on platelet function in vitro and ex vivo and on blood coagulation ex vivo. In the in vitro studies, spontaneous platelet aggregation; platelet aggregation induced by ADP, collagen, and ristocetin; and the release of j(-thromboglobulin from platelets were assessed. Platelets from healthy subjects were incubated with teicoplanin at final concentrations of 100, 1,500, 5,000, and 10,000 t,.g/ml.
Teicoplanin, a new glycopeptide antibiotic active against gram-positive bacteria, is being investigated in several clinical trials in different countries (3, 7) .
Teicoplanin is structurally related to ristocetin, an antibiotic withdrawn from clinical use in the 1960s because it was found to induce thrombocytopenia and thromboembolic side effects (2) . These adverse effects appear to be related to the ability of ristocetin to trigger platelet aggregation by reacting with a specific receptor of the platelet membrane (4) . More specifically, ristocetin induced agglutination of human platelets by promoting the binding of von Willebrand factor molecules to platelet membrane glycoprotein Ib (8) .
Vancomycin, another glycopeptide antibiotic, does not agglutinate platelets in normal platelet-rich plasma (PRP), but it interferes with ristocetin-induced agglutination (6) .
Preliminary studies with animals have excluded the possibility that teicoplanin exerts the same effects on platelets as ristocetin (G. Buniva, personal communication; data on file at Gruppo Lepetit S.p.A., Milan, Italy, 1986), but data for humans are lacking.
The aim of this study was to evaluate the effects of teicoplanin on platelet function in vitro and ex vivo and on blood coagulation ex vivo. The ex vivo studies were done with both normal volunteers and patients affected by teicoplanin-susceptible infections. * Corresponding author.
MATERIALS AND METHODS
In vitro studies. (i) Subjects. Eight healthy subjects (four males and four females) with a mean age of 35 years (range, 23 to 48 years) gave their informed consent to venesection.
None of the subjects had taken any drug known to inhibit platelet function for at least 10 days before venesection. Blood samples were taken after the subjects fasted for at least 12 h.
(ii) Preparation of PRP. An antecubital vein was punctured with a 19-gauge needle, and 4 ml of blood was withdrawn and discarded; then, 18 ml of blood was drawn, with stasis avoided through the same needle, into a second plastic syringe containing 2 ml of 3.8% sodium citrate. After being thoroughly mixed, the sample was immediately centrifuged at 150 x g for 15 min at room temperature (21°C) to obtain PRP, which was removed. The remaining blood was centrifuged at 1,500 x g for 20 min to obtain platelet-poor plasma (PPP). Siliconized glassware was always used. The platelet concentration in the PRP was determined by direct count and then adjusted with autologous PPP to a final concentration of 250,000/mm3.
The interval from the time of sampling to the performance of platelet aggregation studies was less than 3 h, during which time plasma samples were kept at room temperature.
(iii) Platelet aggregation. Platelet aggregation tests were done by the turbidimetric method of Born (1) . A 0.6-ml sample of adjusted PRP was placed in a plastic cuvette containing a plastic-covered stirring bar and stirred at 1,100 rpm in a Bryston aggregometer equipped with a 5117.5 Omniscribe strip chart recorder. In each determination, the extent of light transmission in the aggregometer was standardized so that thp PPP blank would indicate 100% and the PRP sample would indicate 0% light transmission. Platelet aggregation was displayed by a proportional increase in light transmission shifting from that of PRP to that of PPP. For each curve, the maximal amplitude, i.e., the maximal deflection obtained during the registration, was calculated. Spontaneous platelet aggregation and ADP-, collagen-, and ristocetin-induced platelet aggregation were studied. Spontaneous platelet aggregation was studied by placing the sample in the aggregometer and recording the light transmission for 10 min after the addition of different dilutions of teicoplanin. Samples were stirred at 1,100 rpm. ADP-, collagen-, and ristocetin-induced platelet aggregation was studied by adding ADP at a final concentration of 1.5 FiM, collagen at a final concentration of 4 mM, and ristocetin at a final concentration of 1.5 mg/ml to PRP samples preincubated with teicoplanin for 10 min. ADP, collagen, and ristocetin were obtained from Mascia-Brunelli, Milan, Italy. Teicoplanin (Lepetit) was diluted in saline and added to PRP samples to give final concentrations of 100, 1,500, 5,000, and 10,000 ,ug/ml. The concentration achieved in human plasma at therapeutic doses is 100 ,ug/ml. For each of the dilutions, spontaneous platelet aggregation and ADP-, collagen-, and ristocetin-induced platelet aggregation were studied. Samples incubated with saline served as controls. Saline samples were always used for the first test to check whether the platelets responded properly and for the last test to make sure that the PRP had not lost its responsiveness as a result of aging of the bench.
(iv) P3-Thromboglobulin release. The ability of teicoplanin and ristocetin to induce ,-thromboglobulin release from platelets was studied. Teicoplanin, ristocetin, and saline were incubated for 10 min with 1 ml of PRP. The final concentrations of teicoplanin were 100, 1,500, 5,000, and 10,000 jig/ml, and the final concentration of ristocetin was 1.5 mg/ml. After incubation, the PRP was centrifuged at 1,500 x g for 20 min, and samples of supernatant were stored for the P-thromboglobulin assay. The ,-thromboglobulin assay was done by using a radioimmunoassay (Radiochemical Centre, Amersham, England). Ex vivo studies. The ex vivo studies were done with six healthy volunteers (two males and four females with ages ranging from 27 to 32 years) and six patients (three males and three females with ages ranging from 35 to 60 years) who had teicoplanin-susceptible infections. Both groups of subjects had normal hemostatic profiles (for the normal values, see Table 2 ). Teicoplanin was administered intravenously as a single dose of 400 mg on day 1 and then as single doses of 200 mg daily for 7 days. Platelet count, bleeding time, plasma 3-thromboglobulin, activated partial thromboplastin time, prothrombin time, thrombin clotting time, and serum fibrinogen-fibrin degradation products were evaluated at days 0, 3, and 7 of teicoplanin treatment and 3 days after the end of teicoplanin treatment. The blood samples at days 3 and 7 were taken 2 h after teicoplanin administration. Samples for the P-thromboglobulin assay were drawn into polystyrene syringes without venous stasis and immediately mixed with an anticoagulant mixture (EDTA [2.75 mg/ml] and theophylline [0.15 mg/ml]) in melting ice. They were centrifuged within 2 h at 2,000 x g for 30 min at 4°C. The top third of the PPP was removed for the P-thromboglobulin assay by a commercially available radioimmunoassay kit (Radiochemical Centre).
Activated partial thromboplastin time, prothrombin time, and thrombin clotting time were determined by standard methods. The template bleeding time was determined by the method of Mielke et al. (5) by using a standard device (Thrombolette; Boehringer GmbH, Mannheim, Federal Republic of Germany). Fibrinogen-fibrin degradation products were analyzed with the Thrombo-Wellco Test (Wellcome Research Laboratories, Beckenham, England).
In the healthy volunteers, a platelet aggregation study by the method of Born (1) was also done. ADP at concentrations of 2, 4, and 8 ,uM, epinephrine at a concentration of 10 ,uM, and ristocetin at a concentration of 1.5 mg/ml were used.
Untreated healthy volunteers served as controls. None of the subjects had taken any drug known to inhibit platelet function for at least 10 days before the venesection. Blood samples were taken after the subjects fasted for at least 12 h. Statistical analysis. The Wilcoxon two-tailed rank-sum test for paired samples and the Kruskal-Wallis test were used to assess the statistical significance of differences between the results obtained at the three control times and the pretreatment values.
RESULTS
In vitro studies. The results of spontaneous and ADP-, collagen-, and ristocetin-induced platelet aggregation studies are shown in Table 1 . Teicoplanin at concentrations similar to that reached in vivo (100 ,ug/ml) and 15 times higher (1,500 ,ug/ml) neither induced platelet aggregation nor inhibited ADP-, collagen-, and ristocetin-induced platelet aggregation. Ristocetin at a concentration of 1.5 mg/ml induced 58.7% platelet aggregation. The two higher concentrations of teicoplanin, i.e., 50 and 100 times higher than the concentration reached in vivo, both induced significantly greater platelet aggregation than saline did (P < 0.01) and inhibited ADP-, collagen-, and ristocetin-induced platelet aggregation significantly more than saline did (P < 0.01).
The results of the ,-thromboglobulin assay on the supernatant after incubation of PRP with saline, ristocetin, and teicoplanin are shown in Table 1 . The three lower concentrations of teicoplanin, i.e., 100, 1,500, and 5,000 ,ug/ml, did not induce significantly greater release of P-thromboglobulin from platelets than saline did. The highest concentration of teicoplanin, i.e., 10,000 p.g/ml, induced significantly greater release of ,-thromboglobulin than saline did (P < 0.01).
Ristocetin (1.5 mg/ml) induced the greatest release of Pthromboglobulin from platelets.
Ex vivo studies. All subjects completed the study without evidence of any side effects. The results of the ex vivo study in normal volunteers and patients with teicoplanin-susceptible infections are shown in Tables 2 and 3 Teicoplanin has an antibacterial spectrum similar to that of vancomycin, with the advantages of the convenience of a single daily dose and, probably, lower toxicity. However, an evaluation of the effects of teicoplanin on hemostasis has not been done. We have carried out a study to evaluate the effects of teicoplanin on platelet function in vitro and ex vivo and on blood coagulation ex vivo.
In the in vitro studies, teicoplanin at a concentration 15 times higher than that clinically achievable did not induce platelet aggregation or inhibition of collagen-, ADP-, or ristocetin-induced platelet aggregation. At a comparable concentration, i.e., 1.5 mg/ml, vancomycin has been shown to interfere with ristocetin-induced platelet aggregation (6).
3-Thromboglobulin is a platelet-specific protein which is released from platelets after activation.
Teicoplanin did not induce an in vitro release of Ithromboglobulin from platelets until it reached a concentration 50 times higher than that achieved in human plasma at therapeutic doses.
In the ex vivo study, no effect on plasma P-thromboglobulin and ADP-, epinephrine-, and ristocetin-induced platelet aggregation was observed after the infusion of therapeutic doses of teicoplanin. This finding seems to exclude an in vivo interaction between teicoplanin and circulating platelets. The coagulation tests were selected as the most suitable to identify both a drug-induced tendency toward bleeding and an activation of blood coagulation. No effect of teicoplanin treatment on blood coagulation was observed. However, our conclusions do not apply to larger doses of teicoplanin which are used to treat severe infections.
We conclude that platelet function and blood coagulation are not affected by therapeutic concentrations of teicoplanin and that in vitro platelet function is affected only by concentrations of teicoplanin far in excess of those that are clinically achievable. Teicoplanin, therefore, does not seem to have a ristocetintype effect on platelets and, when compared with vancomycin, has a lower ability to interfere with ristocetin-induced platelet aggregation.
